Scilex Holding Company Cash Flow Conversion Efficiency
Scilex Holding Company cash flow conversion efficiency. Based on the latest financial reports, Scilex Holding Company (SCLX) has a cash flow conversion efficiency ratio of 0.022x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.74 Million) by net assets ($-310.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scilex Holding Company (2020–2025)
Cash flow conversion efficiency of Scilex Holding Company from 2020 to 2025. This chart illustrates how Scilex Holding Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SCLX live share price for real-time trading data and today's change.
Scilex Holding Company Cash Flow Conversion Ratio Explained
Scilex Holding Company cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scilex Holding Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scilex Holding Company ranked by their cash flow conversion efficiency. Also see Scilex Holding Company stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
-0.030x |
|
Vizione Holdings Bhd
KLSE:7070
|
-0.027x |
|
TRANSTEMA GROUP AB O.N.
F:9G8
|
0.059x |
|
Edinburgh Investment Trust
LSE:EDIN
|
0.007x |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
-0.026x |
|
Oceanic Beverages Co Inc
TW:1213
|
-0.090x |
|
Jocil Limited
NSE:JOCIL
|
-0.200x |
|
Elementis PLC
LSE:ELM
|
0.069x |
Annual Cash Flow Conversion Efficiency for Scilex Holding Company (2020–2025)
The table below shows the annual cash flow conversion efficiency of Scilex Holding Company from 2020 to 2025. Review Scilex Holding Company (SCLX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-211.75 Million | $3.82 Million | -0.018x | +82.06% |
| 2024-12-31 | $-192.64 Million | $19.35 Million | -0.100x | -183.88% |
| 2023-12-31 | $-172.94 Million | $-20.71 Million | 0.120x | +120.41% |
| 2022-12-31 | $36.24 Million | $-21.26 Million | -0.587x | -558.16% |
| 2021-12-31 | $-223.88 Million | $-28.66 Million | 0.128x | -42.34% |
| 2020-12-31 | $-141.68 Million | $-31.46 Million | 0.222x | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more